Stockscreener 앱 받기
5.63
2.93%
0.16
전일 마감가:
$5.47
열려 있는:
$5.53
하루 거래량:
125.88K
Relative Volume:
11.47
시가총액:
$445.97M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
+0.00%
1개월 성능:
+0.00%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$5.36
$5.70
1주일 범위
$5.10
$5.9299
52주 변동 폭
$5.10
$5.9299
Nervgen Pharma Corp Stock (NGEN) Company Profile
NGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NGEN
Nervgen Pharma Corp
|
5.63 | 433.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Nervgen Pharma Corp 주식(NGEN)의 최신 뉴스
NervGen Pharma Advances NVG-291 for Spinal Cord Injury Treatment - MSN
NervGen Pharma Begins Trading on Nasdaq Today - Sahm
Is NervGen Pharma Corp. (9UA) stock good for wealth creationJuly 2025 Movers & Weekly High Conviction Trade Ideas - Улправда
NervGen Pharma Debuts On Nasdaq - Nasdaq
NervGen Pharma to Begin Trading on Nasdaq - marketscreener.com
NervGen Pharma Lists on Nasdaq to Support Late-Stage Push for Spinal Cord Injury Drug - TipRanks
NervGen Pharma Gets Approval for Listing on Nasdaq - marketscreener.com
NervGen Pharma Brief: Begins Trading on Nasdaq Today - marketscreener.com
This Company’s Drug May Help Regenerate Injured Spinal Cords - Forbes
NervGen Pharma Announces Filing of Form F-10 Registration Statement with The SEC Under MJDS - Yahoo Finance
NervGen Pharma Proposes Amendment to Warrant Terms - TipRanks
This Canadian biotech stock is looking to treat spinal cord injuries - Cantech Letter
NervGen Pharma’s NVG-291 Shows Promising Results in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma Secures $10M to Propel Nasdaq Listing and NVG-291 Development - TipRanks
NervGen Pharma Announces US$10 Million Non-Brokered Private Placement to Support Anticipated Nasdaq Listing and Advance NVG-291 Development - Yahoo Finance
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth? - Yahoo Finance
Pennsylvania man says experimental drug has helped him recover from cycling accident - CBS News
Nervgen Pharma’s NVG-291 Study: A Potential Breakthrough in Spinal Cord Injury Treatment - TipRanks
NervGen Pharma price target chopped at Research Capital - Cantech Letter
NervGen: A High-Stakes Bet on a Groundbreaking Nerve Repair Drug - NAI500
TSX Penny Stocks To Consider In August 2025 - Yahoo Finance
NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury - Yahoo Finance
NervGen Pharma is a buy, Research Capital says - Cantech Letter
NervGen Pharma Establishes Multiple Sclerosis Clinical Advisory Board - TMX Newsfile
NervGen Announces Leadership Transition to Support Strategic Growth and Expansion - Yahoo Finance
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth - Yahoo Finance
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones - Yahoo Finance
Insights on NervGen Pharma’s Positive Phase 1b/2a Data for NVG-291 in Spinal Cord Injury - NeurologyLive
NervGen Pharma: Risky, Yet Promising With Big Upside - Seeking Alpha
TSX Penny Stocks To Watch In June 2025 - Yahoo Finance
Leaders in health care innovation - BNN Bloomberg
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury - Yahoo Finance
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting - Yahoo Finance
NervGen Pharma Reports Q1 2025 Financial Results and Advances NVG-291 Clinical Development - TipRanks
NGENFNervgen Pharma Corp Latest Stock News & Market Updates - Stock Titan
NervGen Pharma is a high-risk, high-reward stock, analyst says - Cantech Letter
NervGen Initiates Expanded Access Policy - Yahoo Finance
Lineage Initiates Clinical Study of OPC1 for Spinal Cord Injury - Business Wire
Repairing Spinal Cord Injury Damage - the-scientist.com
Spinal Cord Injury Treatment Market 2034: EMA, PDMA, FDA Approval, Clinical Trials, Epidemiology, Therapies and Companies by DelveInsight - The Globe and Mail
Undercovered Dozen: OppFi, PowerFleet, Eletrobras, American Battery + - Seeking Alpha
NervGen: Data For Spinal Cord Injury Treatment Candidate Likely For Mid-2025 - Seeking Alpha
NervGen Pharma: Proof that NVG-291 works? | 2024-12-23 | Investing News - Stockhouse
NervGen Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference - TMX Newsfile
Repairing the Spine: Q&A with Mike Kelly, CEO of NervGen - PharmExec.com
NervGen Pharma Appoints Neil Klompas to Board of Directors - TMX Newsfile
NervGen: Are amazing human trial results leaking out? | 2024-07-02 | Investing News - Stockhouse
NervGen Pharma | Biotechnology | The Pharmaletter - The Pharma Letter
Nervgen Pharma advances evaluation of NVG-300 - BioWorld MedTech
NervGen Pharma to Advance NVG-300 into Preclinical Proof-of-Concept Stage - Yahoo Finance
Is This Pharma Co. the Next Eli Lilly? - streetwisereports.com
Nervgen Pharma Corp (NGEN) 재무 분석
Nervgen Pharma Corp (NGEN)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):